HIV Prevention Summit 2021

Slideset

HIV

Novel Drug Delivery Systems on the Horizon - Charles Flexner, MD

Slideset

HIV

Whatever Happened with PEP - Fiona Cresswell, PhD, MBChB, BSc, DTM&H, PGCert Epi, DipGUM, DFSRH

Slideset

HIV

Successful Models of PrEP Implementation - François Venter, MD, FCP, PhD

Slideset

HIV

Successes to Access PrEP and PEP End-User Perspective - Gcobisa Madlolo

Slideset

HIV

The Prevention Pipeline and Clinical Trial Design for PrEP - Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD

Slideset

HIV

Why Don't Prescribers Prescribe - Douglas Krakower, MD

Slideset

HIV

Overview of Clinical Data on the Safety and Efficacy of Antiretroviral Drugs for HIV Prevention - Roy M. Gulick, MD, MPH

Slideset

HIV

WHO Perspective on HIV Prevention - What Are the Gaps - Rachel Baggaley, MBBS, MSc

Slideset

HIV

Antibody Mediated Prevention of HIV - Myron S. Cohen, MD, BS

Slideset

HIV

Socio-Demographics of Individuals Initiated on HIV pre-exposure prophylaxis (PrEP) in Nigeria - Augustine Idemudia

Slideset

HIV

Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis: A Real-World Evidence Analysis in the United States - Corie Cruz Beniasians

Slideset

HIV

Community PrEP Service delivery for Female Sex Workers in Ghana - Guro Lundby Sorensen

Slideset

HIV

Intimate partner violence and gender-based violence among people living with HIV in southern Nigeria - Chika Okafor

Slideset

HIV

Uptake of HIV post-exposure prophylaxis, completion rates and selfreported reasons for non-completion among health care workers at Mbarara Regional Referral Hospital - Musiime Muzoora Dan

Slideset

HIV

Non-Occupational Post-Exposure Prophylaxis, Post-Violence Care and Ongoing HIV Risk in Kampala Uganda: Missed Opportunities for HIV Prevention through Pre-Exposure Prophylaxis and Other Interventions - Lisa Mills

Slideset

HIV

WHO Perspective on HIV Prevention - What Are the Gaps - Rachel Baggaley, MBBS, MSc

Slideset

HIV

Overview of Clinical Data on the Safety and Efficacy of Antiretroviral Drugs for HIV - Roy M. Gulick, MD, MPH

Slideset

HIV

Successes to Access PrEP and PEP End-User Perspective_Gcobisa Madlolo

Slideset

HIV

Successful Models of PrEP Implementation - Francois Venter, MD

Slideset

HIV

Why Don't Prescribers Prescribe - Douglas Krakower, MD

Slideset

HIV

HIV Prevention Summit 2021

Novel Drug Delivery Systems on the Horizon - Charles Flexner, MD

Whatever Happened with PEP - Fiona Cresswell, PhD, MBChB, BSc, DTM&H, PGCert Epi, DipGUM, DFSRH

Successful Models of PrEP Implementation - François Venter, MD, FCP, PhD

Successes to Access PrEP and PEP End-User Perspective - Gcobisa Madlolo

The Prevention Pipeline and Clinical Trial Design for PrEP - Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD

Why Don't Prescribers Prescribe - Douglas Krakower, MD

Overview of Clinical Data on the Safety and Efficacy of Antiretroviral Drugs for HIV Prevention - Roy M. Gulick, MD, MPH

WHO Perspective on HIV Prevention - What Are the Gaps - Rachel Baggaley, MBBS, MSc

Antibody Mediated Prevention of HIV - Myron S. Cohen, MD, BS

Socio-Demographics of Individuals Initiated on HIV pre-exposure prophylaxis (PrEP) in Nigeria - Augustine Idemudia

Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis: A Real-World Evidence Analysis in the United States - Corie Cruz Beniasians

Community PrEP Service delivery for Female Sex Workers in Ghana - Guro Lundby Sorensen

Intimate partner violence and gender-based violence among people living with HIV in southern Nigeria - Chika Okafor

Uptake of HIV post-exposure prophylaxis, completion rates and selfreported reasons for non-completion among health care workers at Mbarara Regional Referral Hospital - Musiime Muzoora Dan

Non-Occupational Post-Exposure Prophylaxis, Post-Violence Care and Ongoing HIV Risk in Kampala Uganda: Missed Opportunities for HIV Prevention through Pre-Exposure Prophylaxis and Other Interventions - Lisa Mills

WHO Perspective on HIV Prevention - What Are the Gaps - Rachel Baggaley, MBBS, MSc

Successes to Access PrEP and PEP End-User Perspective - Gcobisa Madlolo

Antibody Mediated Prevention of HIV - Myron Cohen, MD

Novel Drug Delivery Systems on the Horizon -Charles Flexner, MD

Overview of Clinical Data on the Safety and Efficacy of Antiretroviral Drugs for HIV - Roy M. Gulick, MD, MPH

Successes to Access PrEP and PEP End-User Perspective_Gcobisa Madlolo

Successful Models of PrEP Implementation - Francois Venter, MD

Why Don't Prescribers Prescribe - Douglas Krakower, MD

R&D Pipeline & Clinical Trial Design -Linda-Gail Bekker, DCH, FCP(SA), PhD